Clarifying the categorization of anaphylaxis as an adverse event during oral immunotherapy
J Allergy Clin Immunol
.
2022 Jul;150(1):229-230.
doi: 10.1016/j.jaci.2022.02.032.
Epub 2022 Apr 28.
Authors
Paul J Turner
1
,
Nandinee Patel
2
,
Pablo Rodríguez Del Río
3
Affiliations
1
National Heart and Lung Institute, Imperial College London, London, United Kingdom. Electronic address: p.turner@imperial.ac.uk.
2
National Heart and Lung Institute, Imperial College London, London, United Kingdom.
3
Hospital Universitario Niño Jesús, Madrid, Spain.
PMID:
35491265
DOI:
10.1016/j.jaci.2022.02.032
No abstract available
Publication types
Letter
Comment
MeSH terms
Allergens
Anaphylaxis* / etiology
Desensitization, Immunologic / adverse effects
Humans
Immunotherapy
Substances
Allergens
Grants and funding
MR/K010468/1/MRC_/Medical Research Council/United Kingdom